GlassScriptPhysician profile
Wasim Mansour
NPI 1649627696
$6,120.86
in general payments reported to CMS, 2019-2025
35 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $788 · 2021: $1,586 · 2022: $2,595 · 2023: $372 · 2024: $176 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,860.07 | 2022 | |
| Amgen INC. | $1,130.14 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $338.06 | 2021-2025 | |
| Dexcom, INC. | $294.36 | 2021-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $252.73 | 2020-2022 | |
| Lilly USA, LLC | $248.54 | 2019-2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $198.13 | 2019-2021 | |
| Abbott Laboratories | $189.87 | 2019-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $184.68 | 2020-2025 | Airsupra |
| Esperion Therapeutics, INC. | $180.00 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $166.71 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.31 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.14 | 2020-2021 | |
| Pfizer INC. | $110.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $83.55 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $68.22 | 2023 | Apretude |
| Novo Nordisk INC | $59.94 | 2022 | |
| Janssen Pharmaceuticals, INC | $59.92 | 2021 | |
| Merck Sharp & Dohme LLC | $58.70 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.22 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $37.29 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $33.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.05 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.31 | 2020 | |
| Corium, LLC | $24.30 | 2023 | Adlarity |
| Lundbeck LLC | $21.63 | 2021 | |
| Corcept Therapeutics | $21.39 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $21.19 | 2023 | Gemtesa |
| Therapeuticsmd, INC. | $19.87 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.85 | 2024 | Zoryve |
| Optinose US, INC. | $15.67 | 2024 | |
| Amarin Pharma, INC. | $15.63 | 2020 | |
| Allergan, INC. | $13.84 | 2020 | |
| Cipher Pharmaceuticals US LLC | $13.64 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasim Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.